Have you ever heard of a condition where your immune system gets too overprotective and ends up causing more harm than good?

IGM Biosciences, Inc.’s IGMS share price has dipped by 6.85%, which has investors questioning if this is right time to buy.

Covert or latent Toxoplasma gondii infection is significantly correlated with chronic kidney disease, according to research ...

Immunoglobulin M (IgM) is also one of the first antibodies recruited by the immune system to fight infection. IgM populations rise very quickly when the body is first confronted with an infectious ...

The human immune system is highly complex and well-equipped to combat most bacteria. However, in some instances bacteria can cause life-threatening infections and the increase of antibiotic-resistant ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...

Current IgG tests are up to 97% accurate in detecting HSV-1 and 98% accurate in detecting HSV-2. IgG vs. IgM The IgG test is not the only antibody test that can be used to detect genital herpes. There ...

The levels of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies were significantly higher in patients with NSCLC (P<0.05). Anti-COPT1-IgG and anti-COPT1-IgM could discriminate NSCLC from NC with area ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted. No ...

Severe hypogammaglobulinemia was observed in 5 cases, with one patient requiring immunoglobulin replacement therapy. Additionally, 5 cases of severe infection were noted. 8 cases exhibited decreased ...

IgM is the first antibody to be produced in a humoral immune response and plays an important role in the primary stages of immunity. Here we describe a mouse Fc receptor, designated Fcα/μR ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...